GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (STU:3NK) » Definitions » Accounts Receivable

Alphamab Oncology (STU:3NK) Accounts Receivable : €2.17 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Alphamab Oncology's accounts receivables for the quarter that ended in Dec. 2024 was €2.17 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Alphamab Oncology's Days Sales Outstanding for the quarter that ended in Dec. 2024 was 6.46.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Alphamab Oncology's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was €0.17.


Alphamab Oncology Accounts Receivable Historical Data

The historical data trend for Alphamab Oncology's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Accounts Receivable Chart

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Receivable
Get a 7-Day Free Trial - 1.06 2.10 0.92 2.17

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.10 3.04 0.92 1.69 2.17

Alphamab Oncology Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Alphamab Oncology Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Alphamab Oncology's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=2.167/61.193*91
=6.46

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Alphamab Oncology's accounts receivable are only considered to be worth 75% of book value:

Alphamab Oncology's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(206.127+0.75 * 2.167+0.5 * 10.731-53.762
-0-0)/961.972
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Alphamab Oncology Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Alphamab Oncology Business Description

Traded in Other Exchanges
Address
No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its product pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development.

Alphamab Oncology Headlines

No Headlines